JIB-04, the most advanced preclinical KDM4 inhibitor, inhibits growth and lowers tumor burden in non-small cell lung cancer and breast cancer, both in vitro and animals, and targets KDM4A, KDM4B, and KDM4E [127,128]. Here, KDM4A is linked to breast carcinoma.